Sign in
Taking people in United StatesPhase 3

Esreboxetine compared with placebo for adults with fibromyalgia

Tests esreboxetine against placebo in adults living with fibromyalgia.

Key facts

Who runs it
Axsome Therapeutics, Inc.
Where
Anaheim, Atlanta, Austin, Boston, Brooklyn, Charleston, Chicago, Cranston, Cromwell, Dallas, Duncansville, Glendale, Hartsdale, Hazelwood, High Point, Hollywood, Houston, Huber Heights, Jacksonville, Kansas City, Knoxville, Lakeland, Las Vegas, Little Rock, Louisville, Maitland, Marietta, Memphis, Milford, Norcross, North Dartmouth, Oceanside, Orlando, Overland Park, Phoenix, Plymouth Meeting, Prairieville, Prosper, Redlands, Rockville, Sacramento, San Antonio, Santa Ana, Springfield, Tampa, The Villages, The Woodlands, Tinley Park, Town and Country, Tucson, Tulsa, Watertown, and Williamsville, United StatesSee the 53 sites
Trial code
Registry title
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Status
Recruiting
Phase
Phase 3
People taking part
620 people, planned
Started
14 Jan 2026
Expected to end
Mar 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • AXS-14 (Esreboxetine)
  • Placebo
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with fibromyalgia. It tests AXS-14 (esreboxetine) against a placebo (a dummy pill).

Age
18 years and older
Sex
All sexes
Disease stage
Fibromyalgia as the main diagnosis, based on the 2016 ACR diagnostic criteria.
Earlier treatment
People cannot join if they were in an earlier trial with reboxetine or esreboxetine, or now take reboxetine.

Main reasons for not taking part

  • Earlier participation in a clinical trial with reboxetine or esreboxetine
  • Currently receiving reboxetine for any condition
  • Unable to follow the study procedures
  • The study doctor judges that joining is not medically appropriate

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Has a primary diagnosis of fibromyalgia based on the 2016 ACR diagnostic criteria
  • Male or female, ≥18 years of age
  • Provides written informed consent to participate in the study before conducting any study procedures

Who cannot take part

  • Previous participation in a clinical trial with reboxetine or esreboxetine or currently receiving treatment with reboxetine for any condition
  • Unable to comply with study procedures
  • Medically inappropriate for study participation in the opinion of the investigator

Where in United States

  • Anaheim, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Atlanta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
  • Austin, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Boston, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
  • Brooklyn, New YorkHospital not named in the registryContact: Study DirectorTaking people
  • Charleston, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Chicago, IllinoisHospital not named in the registryContact: Study DirectorTaking people
  • Cranston, Rhode IslandHospital not named in the registryContact: Study DirectorTaking people
  • Cromwell, ConnecticutHospital not named in the registryContact: Study DirectorTaking people
  • Dallas, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Duncansville, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
  • Glendale, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Hartsdale, New YorkHospital not named in the registryContact: Study DirectorTaking people
  • Hazelwood, MissouriHospital not named in the registryContact: Study DirectorTaking people
  • High Point, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Hollywood, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Houston, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Huber Heights, OhioHospital not named in the registryContact: Study DirectorTaking people
  • Jacksonville, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Kansas City, KansasHospital not named in the registryContact: Study DirectorTaking people
  • Knoxville, TennesseeHospital not named in the registryContact: Study DirectorTaking people
  • Lakeland, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Las Vegas, NevadaHospital not named in the registryContact: Study DirectorTaking people
  • Little Rock, ArkansasHospital not named in the registryContact: Study DirectorTaking people
  • Louisville, KentuckyHospital not named in the registryContact: Study DirectorTaking people
  • Maitland, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Marietta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
  • Memphis, TennesseeHospital not named in the registryContact: Study DirectorTaking people
  • Milford, OhioHospital not named in the registryContact: Study DirectorTaking people
  • Norcross, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
  • North Dartmouth, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
  • Oceanside, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Orlando, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Overland Park, KansasHospital not named in the registryContact: Study DirectorTaking people
  • Phoenix, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Plymouth Meeting, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
  • Prairieville, LouisianaHospital not named in the registryContact: Study DirectorTaking people
  • Prosper, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Redlands, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Rockville, MarylandHospital not named in the registryContact: Study DirectorTaking people
  • Sacramento, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • San Antonio, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Santa Ana, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Springfield, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
  • Tampa, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • The Villages, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • The Woodlands, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Tinley Park, IllinoisHospital not named in the registryContact: Study DirectorTaking people
  • Town and Country, MissouriHospital not named in the registryContact: Study DirectorTaking people
  • Tucson, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Tulsa, OklahomaHospital not named in the registryContact: Study DirectorTaking people
  • Watertown, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
  • Williamsville, New YorkHospital not named in the registryContact: Study DirectorTaking people

About the trial

What the trial wants to find out

The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.

The 2 groups in the trial

  • AXS-14 (esreboxetine)Treatment being tested

    * Up to 12 weeks in the open-label period; * Up to 12 weeks in the randomized double-blind period (if applicable)

  • PlaceboPlacebo, for comparison

    • Up to 12 weeks in the randomized double-blind period (if applicable)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia
Plain-language title
Esreboxetine compared with placebo for adults with fibromyalgiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
10 November 2026